Malcolm Kenneth Robinson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bariatric Surgery | 12 | 2023 | 952 | 2.310 |
Why?
|
Obesity, Morbid | 16 | 2023 | 1213 | 2.060 |
Why?
|
Gastric Bypass | 10 | 2023 | 812 | 1.830 |
Why?
|
Nutritional Status | 8 | 2019 | 1609 | 1.160 |
Why?
|
Malnutrition | 7 | 2019 | 625 | 0.930 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2023 | 158 | 0.920 |
Why?
|
Critical Illness | 7 | 2018 | 2670 | 0.910 |
Why?
|
Nutritional Support | 2 | 2018 | 168 | 0.850 |
Why?
|
Obesity | 14 | 2023 | 12742 | 0.820 |
Why?
|
Gastroplasty | 4 | 2016 | 142 | 0.800 |
Why?
|
Ghrelin | 4 | 2013 | 266 | 0.750 |
Why?
|
Nutrition Therapy | 1 | 2020 | 96 | 0.670 |
Why?
|
Osteoarthritis | 1 | 2021 | 1036 | 0.460 |
Why?
|
S Phase | 1 | 2013 | 423 | 0.430 |
Why?
|
G1 Phase | 1 | 2013 | 415 | 0.420 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 480 | 0.420 |
Why?
|
Parenteral Nutrition | 2 | 2015 | 650 | 0.420 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 489 | 0.410 |
Why?
|
Laparoscopy | 4 | 2022 | 2149 | 0.380 |
Why?
|
Depressive Disorder | 1 | 2023 | 3750 | 0.380 |
Why?
|
Abdominal Pain | 1 | 2016 | 1062 | 0.360 |
Why?
|
Gastrectomy | 5 | 2023 | 663 | 0.350 |
Why?
|
Enteral Nutrition | 1 | 2015 | 763 | 0.340 |
Why?
|
Catheterization, Central Venous | 3 | 2013 | 513 | 0.330 |
Why?
|
Weight Loss | 9 | 2023 | 2622 | 0.320 |
Why?
|
Transcriptional Activation | 1 | 2013 | 1782 | 0.300 |
Why?
|
Energy Intake | 1 | 2015 | 2148 | 0.290 |
Why?
|
Hernia, Abdominal | 1 | 2007 | 53 | 0.290 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1525 | 0.280 |
Why?
|
Intestinal Fistula | 1 | 2007 | 140 | 0.280 |
Why?
|
Hospitals | 1 | 2019 | 3952 | 0.270 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 2503 | 0.250 |
Why?
|
Tyramine | 1 | 2023 | 52 | 0.240 |
Why?
|
Selegiline | 1 | 2023 | 31 | 0.240 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2938 | 0.240 |
Why?
|
Hernia, Hiatal | 2 | 2016 | 79 | 0.220 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3023 | 0.220 |
Why?
|
Intestinal Mucosa | 1 | 2013 | 3036 | 0.210 |
Why?
|
Osteoarthritis, Knee | 2 | 2023 | 1222 | 0.210 |
Why?
|
Critical Care | 1 | 2015 | 2644 | 0.210 |
Why?
|
Anastomotic Leak | 1 | 2023 | 162 | 0.200 |
Why?
|
Calciphylaxis | 1 | 2023 | 124 | 0.200 |
Why?
|
Digestive System Surgical Procedures | 1 | 2007 | 576 | 0.200 |
Why?
|
Epithelial Cells | 1 | 2013 | 3690 | 0.200 |
Why?
|
Hypercalcemia | 1 | 2023 | 407 | 0.190 |
Why?
|
Intestine, Small | 1 | 2007 | 1241 | 0.190 |
Why?
|
Intensive Care Units | 4 | 2018 | 3680 | 0.190 |
Why?
|
Nutrition Assessment | 1 | 2003 | 723 | 0.180 |
Why?
|
North America | 1 | 2023 | 1250 | 0.180 |
Why?
|
Tyrosine | 1 | 2023 | 1461 | 0.170 |
Why?
|
Cost-Benefit Analysis | 4 | 2023 | 5396 | 0.160 |
Why?
|
Humans | 41 | 2023 | 744220 | 0.150 |
Why?
|
Patient Care Team | 3 | 2009 | 2529 | 0.140 |
Why?
|
Patient Admission | 1 | 2003 | 1380 | 0.140 |
Why?
|
Menstruation Disturbances | 1 | 2016 | 148 | 0.130 |
Why?
|
Spain | 1 | 2017 | 465 | 0.130 |
Why?
|
Body Mass Index | 4 | 2019 | 12718 | 0.130 |
Why?
|
Nutritional Requirements | 2 | 2015 | 286 | 0.130 |
Why?
|
Calorimetry, Indirect | 1 | 2015 | 183 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 20123 | 0.120 |
Why?
|
Female | 23 | 2023 | 380197 | 0.120 |
Why?
|
Communication Barriers | 1 | 2017 | 398 | 0.120 |
Why?
|
Retrospective Studies | 10 | 2023 | 77426 | 0.110 |
Why?
|
Gastroesophageal Reflux | 3 | 2016 | 782 | 0.110 |
Why?
|
Caco-2 Cells | 1 | 2013 | 387 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 964 | 0.110 |
Why?
|
Macrophages | 1 | 2007 | 5657 | 0.110 |
Why?
|
Databases, Factual | 2 | 2019 | 7730 | 0.110 |
Why?
|
Cytokines | 1 | 2007 | 7326 | 0.110 |
Why?
|
Ultrasonography | 1 | 2005 | 5982 | 0.100 |
Why?
|
Male | 20 | 2023 | 350027 | 0.100 |
Why?
|
Boston | 4 | 2017 | 9311 | 0.100 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2023 | 1458 | 0.100 |
Why?
|
Vitamins | 1 | 2020 | 1621 | 0.100 |
Why?
|
Data Interpretation, Statistical | 1 | 2021 | 2715 | 0.100 |
Why?
|
Thinness | 1 | 2015 | 479 | 0.100 |
Why?
|
Intussusception | 1 | 2012 | 115 | 0.100 |
Why?
|
Postoperative Complications | 2 | 2012 | 15294 | 0.090 |
Why?
|
Patient Education as Topic | 3 | 2017 | 2277 | 0.090 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 252 | 0.090 |
Why?
|
Rest | 1 | 2015 | 901 | 0.090 |
Why?
|
Pharmaceutical Services | 1 | 2011 | 140 | 0.090 |
Why?
|
Quality of Health Care | 1 | 2005 | 4371 | 0.090 |
Why?
|
Catheterization, Peripheral | 1 | 2013 | 344 | 0.090 |
Why?
|
Metabolome | 1 | 2016 | 895 | 0.090 |
Why?
|
Infertility | 1 | 2016 | 655 | 0.090 |
Why?
|
Treatment Outcome | 7 | 2023 | 63119 | 0.090 |
Why?
|
Adult | 16 | 2017 | 214035 | 0.080 |
Why?
|
Survivors | 2 | 2017 | 2291 | 0.080 |
Why?
|
Blood Pressure | 1 | 2023 | 8551 | 0.080 |
Why?
|
Satiety Response | 1 | 2007 | 49 | 0.080 |
Why?
|
Mass Screening | 1 | 2003 | 5252 | 0.080 |
Why?
|
Signal Transduction | 2 | 2007 | 23404 | 0.080 |
Why?
|
Language | 1 | 2017 | 1471 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2020 | 3297 | 0.070 |
Why?
|
Peptide YY | 1 | 2007 | 130 | 0.070 |
Why?
|
Transcription Factor RelA | 1 | 2007 | 275 | 0.070 |
Why?
|
Reimbursement Mechanisms | 2 | 2009 | 670 | 0.070 |
Why?
|
Health Services Accessibility | 2 | 2017 | 5138 | 0.070 |
Why?
|
Middle Aged | 14 | 2017 | 213367 | 0.070 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 697 | 0.060 |
Why?
|
Cohort Studies | 3 | 2023 | 40559 | 0.060 |
Why?
|
Aged | 8 | 2023 | 163253 | 0.060 |
Why?
|
Radiology, Interventional | 1 | 2008 | 460 | 0.060 |
Why?
|
Retinol-Binding Proteins | 1 | 2003 | 65 | 0.060 |
Why?
|
Perioperative Care | 1 | 2011 | 1000 | 0.060 |
Why?
|
Energy Metabolism | 1 | 2015 | 2895 | 0.060 |
Why?
|
Pilot Projects | 1 | 2017 | 8321 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2370 | 0.060 |
Why?
|
Glucagonoma | 1 | 2002 | 14 | 0.060 |
Why?
|
Follow-Up Studies | 4 | 2016 | 39045 | 0.060 |
Why?
|
Societies, Medical | 1 | 2015 | 3741 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10949 | 0.060 |
Why?
|
United States | 5 | 2020 | 69867 | 0.050 |
Why?
|
Peptide Hormones | 1 | 2003 | 134 | 0.050 |
Why?
|
Glutamine | 1 | 2005 | 578 | 0.050 |
Why?
|
Phosphorylation | 1 | 2013 | 8437 | 0.050 |
Why?
|
Interleukin-10 | 1 | 2007 | 1200 | 0.050 |
Why?
|
Prealbumin | 1 | 2003 | 210 | 0.050 |
Why?
|
Interleukin-1beta | 1 | 2007 | 972 | 0.050 |
Why?
|
Short Bowel Syndrome | 1 | 2005 | 345 | 0.050 |
Why?
|
Hypothalamus | 1 | 2007 | 1063 | 0.050 |
Why?
|
Erythema | 1 | 2002 | 257 | 0.050 |
Why?
|
Venous Thromboembolism | 1 | 2013 | 1670 | 0.050 |
Why?
|
Risk Factors | 6 | 2019 | 72280 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15070 | 0.050 |
Why?
|
Serum Albumin | 1 | 2003 | 676 | 0.050 |
Why?
|
Pharynx | 1 | 2003 | 413 | 0.050 |
Why?
|
Human Growth Hormone | 1 | 2005 | 683 | 0.050 |
Why?
|
Prospective Studies | 7 | 2016 | 53280 | 0.050 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 2216 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14726 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2005 | 1682 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2013 | 2862 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2011 | 3528 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 21752 | 0.040 |
Why?
|
Reoperation | 3 | 2012 | 4203 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2211 | 0.040 |
Why?
|
Patient Selection | 3 | 2020 | 4216 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2008 | 2708 | 0.040 |
Why?
|
Wasting Syndrome | 1 | 2017 | 101 | 0.040 |
Why?
|
Hypoxanthine | 1 | 2016 | 28 | 0.040 |
Why?
|
Amino Acids | 1 | 2002 | 1734 | 0.040 |
Why?
|
Pyrrolidonecarboxylic Acid | 1 | 2016 | 65 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4419 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 13885 | 0.030 |
Why?
|
Antacids | 1 | 2016 | 99 | 0.030 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2012 | 1812 | 0.030 |
Why?
|
Pancreatic Neoplasms | 2 | 2003 | 5257 | 0.030 |
Why?
|
Glutamates | 1 | 2016 | 398 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2007 | 5096 | 0.030 |
Why?
|
Warfarin | 1 | 2023 | 1496 | 0.030 |
Why?
|
Fatty Acids | 1 | 2002 | 1808 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2023 | 1787 | 0.030 |
Why?
|
Glutathione | 1 | 2016 | 588 | 0.030 |
Why?
|
Phlebitis | 1 | 2013 | 31 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4929 | 0.030 |
Why?
|
Purines | 1 | 2016 | 594 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2009 | 3611 | 0.030 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 302 | 0.030 |
Why?
|
Bariatric Medicine | 1 | 2011 | 12 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2007 | 19227 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2003 | 3778 | 0.030 |
Why?
|
Rats | 1 | 2007 | 24273 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2008 | 2272 | 0.020 |
Why?
|
Length of Stay | 1 | 2003 | 6308 | 0.020 |
Why?
|
Sex Factors | 2 | 2015 | 10396 | 0.020 |
Why?
|
Jejunum | 1 | 2012 | 480 | 0.020 |
Why?
|
Comorbidity | 2 | 2015 | 10387 | 0.020 |
Why?
|
Incidence | 3 | 2013 | 20945 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1781 | 0.020 |
Why?
|
Logistic Models | 1 | 2003 | 13409 | 0.020 |
Why?
|
Birth Weight | 1 | 2016 | 2069 | 0.020 |
Why?
|
Time Factors | 2 | 2007 | 40063 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2012 | 788 | 0.020 |
Why?
|
Diet | 1 | 2005 | 7937 | 0.020 |
Why?
|
Pregnancy | 3 | 2016 | 29142 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2015 | 15538 | 0.020 |
Why?
|
Canada | 1 | 2012 | 2065 | 0.020 |
Why?
|
Medically Underserved Area | 1 | 2009 | 253 | 0.020 |
Why?
|
Health Policy | 2 | 2009 | 2661 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2016 | 2796 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2012 | 13990 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2003 | 6352 | 0.020 |
Why?
|
Animals | 2 | 2007 | 168788 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2011 | 950 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9849 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2759 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13668 | 0.020 |
Why?
|
Patient Discharge | 1 | 2017 | 3313 | 0.020 |
Why?
|
Food Hypersensitivity | 1 | 2011 | 622 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2005 | 665 | 0.010 |
Why?
|
Equipment Design | 1 | 2012 | 3582 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1504 | 0.010 |
Why?
|
Specialization | 1 | 2009 | 777 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3114 | 0.010 |
Why?
|
Sepsis | 1 | 2017 | 2593 | 0.010 |
Why?
|
Prosthesis Failure | 1 | 2008 | 1206 | 0.010 |
Why?
|
Cachexia | 1 | 2003 | 204 | 0.010 |
Why?
|
Androstadienes | 1 | 2003 | 346 | 0.010 |
Why?
|
Mice | 1 | 2007 | 81178 | 0.010 |
Why?
|
Medicine | 1 | 2009 | 946 | 0.010 |
Why?
|
Probability | 1 | 2005 | 2505 | 0.010 |
Why?
|
Preoperative Care | 1 | 2009 | 2246 | 0.010 |
Why?
|
Neoplasms | 1 | 2008 | 21672 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18367 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2003 | 1618 | 0.010 |
Why?
|
Electromyography | 1 | 2003 | 1391 | 0.010 |
Why?
|
Administration, Oral | 1 | 2005 | 3913 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 29050 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 6367 | 0.010 |
Why?
|
Polysomnography | 1 | 2003 | 1775 | 0.010 |
Why?
|
Syndrome | 1 | 2002 | 3250 | 0.010 |
Why?
|
Massachusetts | 1 | 2009 | 8663 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4567 | 0.010 |
Why?
|
Risk Assessment | 2 | 2009 | 23337 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 25043 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2003 | 6313 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2003 | 3614 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7179 | 0.010 |
Why?
|
Coronary Disease | 1 | 2009 | 6078 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2005 | 8628 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 7908 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8480 | 0.010 |
Why?
|
Prevalence | 1 | 2009 | 15226 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7281 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2005 | 12035 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2009 | 19907 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 57768 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 56436 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 11732 | 0.010 |
Why?
|
Palliative Care | 1 | 2002 | 3490 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2009 | 15161 | 0.000 |
Why?
|